Apixaban versus warfarin in patients with atrial fibrillation

Cited by (1,013)

Items 801–900 of 1,013

1. Edoxaban: Impact on routine and specific coagulation assays
   Bernard Châtelain, Christian Chatelain, Jonathan Douxfils, Jean‐Michel Dogné, François Mullier · 2015 · Thrombosis and Haemostasis
2. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
   Robert Patrick Giugliano, Christian Thomas Ruff, Stephen D. Wiviott, Francesco Nordio, Sabina A. Murphy, Johannes A.N. Kappelhof, Minggao Shi, Michele F. Mercuri, Elliott Marshall Antman, Eugene Braunwald M. D · 2016 · The American Journal of Medicine
3. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis
   Ronpichai Chokesuwattanaskul, Charat Thongprayoon, Tarun Jacob Bathini, Aldo Torres‐Ortiz, O.A. O’Corragain, Kanramon Watthanasuntorn, Ploypin Lertjitbanjong, Konika Sharma, Somchai Prechawat, Patompong Ungprasert et al. · 2018 · Digestive and Liver Disease
4. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people
   Olivier Hanon, Patrick Assayag, Joël Belmin, Jean‐Philippe Collet, J.P. Émeriau, Laurent Fauchier, Françoise Forette, Patrick Friocourt, Armelle Gentric, Christophe Leclercq et al. · 2013 · Archives of cardiovascular diseases
5. New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
   Partha Sardar, Saurav Chatterjee, Wen‐Chih Wu, Edgar Lichstein, Joydeep Ghosh, Shamik Aikat, Debabrata Mukherjee · 2013 · PLoS ONE
6. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
   on behalf of Grupo de trabajo de Riesgo vascular de la SEMI, Carmen Suárez Fernández, Francesç Formiga, Miguel Camafort, J.M. Cepeda Rodrigo, Jesús Díez‐Manglano, Antonio Pose Reino, Gregorio Tiberio, José María Mostaza · 2015 · BMC Cardiovascular Disorders
7. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
   Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric H. Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Yi-Hsuan Chen, Shigeru Saito et al. · 2018 · American Heart Journal
8. Factor XI inhibitors: cardiovascular perspectives
   Raffaele De Caterina, Domenico Prisco, John W. Eikelboom · 2022 · European Heart Journal
9. Geographic Differences in Heart Failure Trials
   João Pedro Ferreira, Nicolas Girerd, Patrick Rossignol, Faiez M. Zannad · 2015 · European Journal of Heart Failure
10. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation
    Mika Skeppholm, Fadiea Al-Aieshy, Maria Berndtsson, Faris Al‐Khalili, Yuko Rönquist-Nii, Lisbeth Söderblom, A. Östlund, Anton Pohanka, Jovan P. Antović, Rickard E. Malmström · 2015 · Thrombosis Research
11. The Discovery of Dabigatran Etexilate
    Joanne van Ryn, Ashley Goss, Norbert H. Hauel, Wolfgang Wienen, Henning W. M. Priepke, Herbert Nar, Andreas Clemens · 2013 · Frontiers in Pharmacology
12. Adherence to long‐term anticoagulation treatment, what is known and what the future might hold
    J. Bartoli-Abdou, Vivian Auyeung, Jignesh Prakash Patel, Roopen Arya · 2016 · British Journal of Haematology
13. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
    Brenda B. Cirincione, Kenneth G. Kowalski, Jace C. Nielsen, Amit Roy, Neelima Thanneer, Wonkyung Byon, Rebecca A. Boyd, Xiaoli Wang, Tarek A. Leil, Frank P. LaCreta et al. · 2018 · CPT Pharmacometrics & Systems Pharmacology
14. In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers
    Y. Whitney Cheung, Stefano Barco, Barbara A. Hutten, Joost C.M. Meijers, Saskia Middeldorp, Michiel Coppens · 2015 · Journal of Thrombosis and Haemostasis
15. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
    Tereza Lanitis, François-Emery Cotté, Anne-Françoise Gaudin, Isabelle Kachaner, Thitima Kongnakorn, Isabelle Durand‐Zaleski · 2014 · Journal of Medical Economics
16. Novel oral anticoagulants and reversal agents: Considerations for clinical development
    Troy C. Sarich, Jonathan H. Seltzer, Scott D. Berkowitz, James C. Costin, John T. Curnutte, Charles Michael Gibson, Maureane Hoffman, Edvardas Kaminskas, Mitchell W. Krucoff, Jerrold H. Levy et al. · 2015 · American Heart Journal
17. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban
    Adewale Alade Fawole, Hamed A. Daw, Mark Andrew Crowther · 2013 · Cleveland Clinic Journal of Medicine
18. Thrombo-embolic prevention after transcatheter aortic valve implantation
    Pascal Vranckx, Stephan Windecker, Robert C. Welsh, Marco Valgimigli, Roxana Mehran, George Dangas · 2017 · European Heart Journal
19. Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016
    Matthew James Alcusky, David D. McManus, Anne Lamont Hume, Marc Fisher, Jennifer Tjia, Kate L. Lapane · 2019 · Journal of the American Heart Association
20. Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients
    Eva Freisinger, Joachim Gerß, Lena Makowski, Ursula Marschall, Holger Reinecke, Helmut Baumgartner, Jeanette Koeppe, Gerhard‐Paul Diller · 2020 · European Heart Journal
21. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
    Shadi R. Yaghi, Nils Henninger, James A. Giles, Christopher R. Leon Guerrero, Eva A. Mistry, Ava Leigh Liberman, Daniyal Asad, Angela Liu, Muhammad Nagy, Ashutosh Kaushal et al. · 2021 · Journal of Neurology Neurosurgery & Psychiatry
22. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis
    Jin Hean Koh, Zi Hui Liew, Gin Kee Ng, Huiting Liu, Yew Chong Tam, Andrea De Gottardi, Yu Jun Wong · 2021 · Digestive and Liver Disease
23. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
    Stylianos E. Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, Eduardo Saad, Alireza Sepehri Shamloo, Jason G. Andrade, Chirag R. Barbhaiya, Tina Baykaner, Serge Bovéda, Hugh G Calkins et al. · 2024 · Journal of Arrhythmia
24. Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions
    Davide Capodanno, Dominick Joseph Angiolillo · 2014 · Circulation Cardiovascular Interventions
25. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage
    Solveig Horstmann, Christian Zugck, Ulrike Krumsdorf, Timolaos Rizos, Geraldine Rauch, Nicolas A. Geis, Stefan E. Hardt, Roland C. Veltkamp · 2013 · Neurology
26. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
    Arlene M. Gallagher, Tjeerd Pieter van Staa, Tarita Murray‐Thomas, Nils Schoof, Andreas Clemens, Diana Ackermann, Dorothee B. Bartels · 2014 · BMJ Open
27. Risk of Intracranial Hemorrhage in Ground‐level Fall With Antiplatelet or Anticoagulant Agents
    Michael Ganetsky, Gregory J. Lopez, Tara Coreanu, Victor Novack, Steven Horng, Nathan Ivan Shapiro, Kenneth Alan Bauer · 2017 · Academic Emergency Medicine
28. Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Eyal Herzog, Ramez S. Nairooz, Debabrata Mukherjee, Jonathan L. Halperin · 2014 · Canadian Journal of Cardiology
29. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)
    Maurizio Giuseppe Abrignani, Luigi Gatta, Domenico Gabrielli, Giuseppe Milazzo, Vincenzo De Francesco, Leonardo De Luca, Maura Francese, Massimo Imazio, Elisabetta Riccio, Roberta Rossini et al. · 2020 · European Journal of Internal Medicine
30. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options
    Bruce Sheldon Stambler, Leonard Mzee Ngunga · 2015 · International Journal of General Medicine
31. Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients – Insight From the Fushimi AF Registry –
    Yasuhiro Hamatani, Hisashi Ogawa, Ryuji Uozumi, Moritake Iguchi, Yugo Yamashita, Masahiro Esato, Yeong‐Hwa Chun, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa et al. · 2015 · Circulation Journal
32. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
    Christopher Bull Granger, Renato D. Lópes, Michael Hanna, Jack Ansell, Elaine M. Hylek, John Hunter Alexander, Laine Elliott Thomas, Junyuan Wang, Maria Cecilia Bahit, Freek W.A. Verheugt et al. · 2014 · American Heart Journal
33. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation
    Pavel Goriacko, Keith T. Veltri · 2018 · European Journal Of Haematology
34. Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation
    Inmaculada Hernandez, Meiqi He, Nemin Chen, Maria M. Brooks, Samir Saba, Walid F. Gellad · 2019 · Journal of the American Heart Association
35. Reversal of drug‐induced anticoagulation: old solutions and new problems
    Sunny Dzik · 2012 · Transfusion
36. The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review
    Megha Agarwal, Stavros Z. Apostolakis, Deirdre A. Lane, Gregory Y.H. Lip · 2014 · Clinical Therapeutics
37. Direct oral anticoagulants: a review on the current role and scope of reversal agents
    Rahul Chaudhary, Tushar Sharma, Jalaj Garg, Ajaypaul Sukhi, Kevin P. Bliden, Udaya S. Tantry, Mohit K. Turagam, Dhanunjaya Lakkireddy, Paul Alfred Gurbel · 2019 · Journal of Thrombosis and Thrombolysis
38. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
    Pierre R. Tibi, Robert Scott McClure, Jiapeng Huang, Robert A. Baker, David C Fitzgerald, C. David Mazer, Marc E. Stone, Danny Chu, Alfred H. Stammers, Tim Dickinson et al. · 2021 · Journal of ExtraCorporeal Technology
39. Protein adsorption on blood-contacting surfaces: A thermodynamic perspective to guide the design of antithrombogenic polymer coatings
    Matthew Crago, Aeryne Lee, Thanh Phuong Hoang, Sepehr Talebian, Sina Naficy · 2024 · Acta Biomaterialia
40. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis
    Ghazi Alotaibi, Hind Almodaimegh, Michael Sean McMurtry, Cynthia M. Wu · 2013 · Thrombosis Research
41. The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey
    Mauro Molteni, Hernan Polo Friz, Laura PRIMITZ, Giuseppe Marano, Patrizia Boracchi, Claudio Cimminiello · 2014 · EP Europace
42. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients
    Daehoon Kim, Pil‐Sung Yang, Eunsun Jang, Hee Tae Yu, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Jung‐Hoon Sung, Hui‐Nam Pak, Moon‐Hyoung Lee et al. · 2019 · EP Europace
43. Atrial Fibrillation, Type 2 Diabetes, and Non–Vitamin K Antagonist Oral Anticoagulants
    Anna Plitt, Darren K. McGuire, Robert Patrick Giugliano · 2017 · JAMA Cardiology
44. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
    Jing Zang Tao, Elena N. Bukanova, Shamsuddin Akhtar · 2018 · Journal of Intensive Care
45. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
    Jean‐Pierre Bassand, Saverio Virdone, Marc Badoz, Freek W.A. Verheugt, A. John Camm, Frank J.S. Cools, Keith A.A. Fox, Samuel Zachary Goldhaber, Shinya Goto, Sylvia K. Haas et al. · 2021 · Blood Advances
46. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
    Nannan Shen, Chi Zhang, Ying Hang, Zheng Li, Ling-Cong Kong, Na Wang, Jialiang Wang, Zhi‐Chun Gu · 2021 · Frontiers in Pharmacology
47. Management of Atrial Fibrillation in Critically Ill Patients
    Mattia Arrigo, Dominique Béttex, Alain Rudiger · 2014 · Critical Care Research and Practice
48. New oral anticoagulants in elderly patients
    Stefano Barco, Y. Whitney Cheung, John W. Eikelboom, Michiel Coppens · 2013 · Best Practice & Research Clinical Haematology
49. Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry
    Benjamin Adam Steinberg, Rosalia G Blanco, Donna M Ollis, Sunghee Kim, DaJuanicia N. Holmes, Peter Russell Kowey, Gregg C. Fonarow, Jack Ansell, Bernard John Gersh, Alan S. Go et al. · 2014 · American Heart Journal
50. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
    Jordan K. Schaefer, Robert D. McBane, Waldemar E. Wysokiński · 2015 · Annals of Hematology
51. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population
    Alpesh Amin, Allison V. Keshishian, Jeffrey N. Trocio, Oluwaseyi Dina, Hannah Le, Lisa C. Rosenblatt, Xianchen Liu, Jack Mardekian, Qisu Zhang, Onur Başer et al. · 2017 · Current Medical Research and Opinion
52. Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
    Nemin Chen, Pamela L. Lutsey, Richard F. MacLehose, J’Neka S. Claxton, Faye L. Norby, Alanna M. Chamberlain, Lindsay G.S. Bengtson, Wesley T. O’Neal, Lin Y. Chen, Álvaro Alonso · 2018 · Journal of the American Heart Association
53. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 9519 patients
    Andersson, Tommy, Magnuson, Anders, Bryngelsson, Ing-Liss, Frøbert, Ole, Henriksson, Karin M., Edvardsson, Nils, Poçi, Dritan · 2014 · International Journal of Cardiology
54. New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications
    Erhard Seifried, Wolfgang Miesbach · 2012 · Thrombosis and Haemostasis
55. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
    Roger E. G. Schutgens, Víctor Jiménez‐Yuste, Miguel Antonio Escobar, Anna Falanga, Bruna Gigante, Robert Klamroth, Riitta Lassila, Frank W.G. Leebeek, Michael Makris, Tarek M. Owaidah et al. · 2023 · HemaSphere
56. Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?
    Graeme J. Hankey · 2014 · Current Cardiology Reports
57. New oral anticoagulants: a practical guide for physicians
    Rocío Hinojar, Jose Julio Jiménez-Natcher, Covadonga Fernández‐Golfín, José Luis Zamorano · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
58. Design of Major Randomized Trials
    Stuart Pocock, Tim C. Clayton, Gregg W. Stone · 2015 · Journal of the American College of Cardiology
59. Adsorption in a Fixed-Bed Column and Stability of the Antibiotic Oxytetracycline Supported on Zn(II)-[2-Methylimidazolate] Frameworks in Aqueous Media
    Janine dos Santos Ferreira da Silva, Daniel López-Malo, Giovana A. Bataglion, Marcos N. Eberlin, Célia M. Machado Ronconi, Severino Alves, Gilberto Fernandes de Sá · 2015 · PLoS ONE
60. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation
    Álvaro Alonso, Richard F. MacLehose, Lin Y. Chen, Lindsay G.S. Bengtson, Alanna M. Chamberlain, Faye L. Norby, Pamela L. Lutsey · 2017 · Heart
61. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke
    Ying Xian, Jerome Jeffrey Federspiel, Adrian F. Hernandez, Daniel T. Laskowitz, Lee H. Schwamm, Deepak L. Bhatt, Eric Edward Smith, Gregg C. Fonarow, Eric David Peterson · 2017 · Circulation
62. Dissection of Cervical and Cerebral Arteries
    Stefan T. Engelter, Christopher Traenka, Philippe A. Lyrer · 2017 · Current Neurology and Neuroscience Reports
63. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
    Guowei Li, Gregory Y.H. Lip, Anne Marie Holbrook, Yaping Chang, Torben Bjerregaard Larsen, Xin Sun, Jie Tang, Lawrence C. E. Mbuagbaw, Daniel M. Witt, Mark Andrew Crowther et al. · 2018 · European Journal of Epidemiology
64. Stroke Prevention in Nonvalvular Atrial Fibrillation
    Mohamad Adnan Alkhouli, Peter A. Noseworthy, Charanjit S. Rihal, David R. Holmes · 2018 · Journal of the American College of Cardiology
65. Fragility Index in Cardiovascular Randomized Controlled Trials
    Muhammad Shahzeb Khan, Rohan Kumar Ochani, Asim Shaikh, Muhammad Usman, Naser Yamani, Safi Ullah Khan, Mohammad Hassan Murad, John M. Mandrola, Rami Doukky, Richard A. Krasuski · 2019 · Circulation Cardiovascular Quality and Outcomes
66. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial
    Justin Adrian Ezekowitz, Basil S. Lewis, Renato D. Lópes, DANIEL M. WOJDYLA, John J.V. McMurray, Michael Hanna, Dan Atar, Maria Cecilia Bahit, Mátyás Keltai, Jose Luis Lopez-Sendon et al. · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
67. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta‐Analysis
    Larisa G. Tereshchenko, Charles A. Henrikson, Joaquin E. Cigarroa, Jonathan S. Steinberg · 2016 · Journal of the American Heart Association
68. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients
    Charles Michael Gibson, Gerald Chi, Rim N. Halaby, Serge Korjian, Yazan Daaboul, Purva Jain, Douglas F. Arbetter, Samuel Zachary Goldhaber, Russel D. Hull, Adrian F. Hernandez et al. · 2016 · Circulation
69. Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation ― Findings From the SAKURA AF Registry ―
    Yasuo Okumura, Katsuaki Yokoyama, Naoya Matsumoto, Eizo Tachibana, Keiichiro Kuronuma, Koji Oiwa, Michiaki Matsumoto, Toshiaki Kojima, Shoji Hanada, Kazumiki Nomoto et al. · 2018 · Circulation Journal
70. Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician. An International Consensus Paper
    Tatjana Potpara, Marek Grygier, Karl Georg Hæusler, Jens Erik Nielsen‐Kudsk, Sérgio Luis Berti, Simonetta Genovesi, Éloi Marijon, Serge Bovéda, Apostolos Tzikas, Giuseppe Boriani et al. · 2024 · EP Europace
71. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
    Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti, START-Register · 2015 · PLoS ONE
72. Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?
    Andreas Clemens, Andreas Strack, Herbert Noack, Stavros Konstantinides, Martina Brueckmann, Gregory Y.H. Lip · 2014 · Annals of Medicine
73. Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation
    Rui Andre Providencia, Éloi Marijon, Serge Bovéda, Sérgio Barra, Kumar Narayanan, Jean‐Yves Le Heuzey, Bernard John Gersh, Lino Manuel Martins Gonçalves · 2014 · The American Journal of Cardiology
74. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
    Sally Lee, Brigitta U. Monz, Andreas Clemens, Martina Brueckmann, Gregory Y.H. Lip · 2012 · BMJ Open
75. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
    Thomas Vanassche, Jack Hirsh, Jeffrey S. Ginsberg, John W. Eikelboom · 2014 · Thrombosis and Haemostasis
76. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
    Kevin L. Thomas, Larry R. Jackson, Peter J. Shrader, Jack Ansell, Gregg C. Fonarow, Bernard John Gersh, Peter Russell Kowey, Kenneth W. Mahaffey, Daniel E. Singer, Laine Elliott Thomas et al. · 2017 · Journal of the American Heart Association
77. Safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: Meta‐analysis
    Ronpichai Chokesuwattanaskul, Charat Thongprayoon, Tanyanan Tanawuttiwat, Wisit Kaewput, Pavida Pachariyanon, Wisit Cheungpasitporn · 2018 · Pacing and Clinical Electrophysiology
78. Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients
    Yan‐Guang Li, So‐Ryoung Lee, Eue‐Keun Choi, Gregory Y.H. Lip · 2018 · Korean Circulation Journal
79. New‐onset postoperative atrial fibrillation after heart surgery
    Tómas Guðbjartsson, Sólveig Helgadóttir, Martin Ingi Sigurdsson, Amar Taha, Anders Jeppsson, Thomas Decker Christensen, Lars Peter Riber · 2019 · Acta Anaesthesiologica Scandinavica
80. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
    Charles V. Pollack, Jeffrey Ian Weitz · 2015 · Thrombosis and Haemostasis
81. Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
    Soyon Lee, Rachel Mullin, Jon Blazawski, Craig Ian Coleman · 2012 · PLoS ONE
82. Determination of Rivaroxaban in Human Plasma Samples
    Job Harenberg, Sandra Erdle, Svetlana Marx, Roland Krämer · 2012 · Seminars in Thrombosis and Hemostasis
83. Utilization and prescribing patterns of direct oral anticoagulants
    Maegan Whitworth, Krystal K. Haase, David S. Fike, Ravindra Bharadwaj, Rodney B. Young, Eric J. MacLaughlin · 2017 · International Journal of General Medicine
84. Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
    Chun‐Li Wang, Victor Chien‐Chia Wu, Chang‐Fu Kuo, Pao‐Hsien Chu, Hsiao‐Jung Tseng, Ming‐Shien Wen, Shang‐Hung Chang · 2018 · Journal of the American Heart Association
85. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation
    Eric H. Van Ganse, Nicolas Danchin, Isabelle Mahé, Olivier Hanon, Flore Jacoud, Maëva Nolin, Faustine Dalon, Cinira Lefèvre, François-Emery Cotté, Sabrina Gollety et al. · 2020 · Stroke
86. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.
    Pierre R. Tibi, Robert Scott McClure, Jiapeng Huang, Robert A. Baker, David C Fitzgerald, C. David Mazer, Marc E. Stone, Danny Chu, Alfred H. Stammers, Tim Dickinson et al. · 2021 · PubMed Central
87. The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
    Grzegorz Grześk, Daniel Rogowicz, Łukasz Wołowiec, Agnieszka Ratajczak, Wojciech Gilewski, Małgorzata Chudzińska, Anna Sinkiewicz, Joanna Banach · 2021 · International Journal of Molecular Sciences
88. Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase
    Wayneho Kam, DaJuanicia N. Holmes, Adrian F. Hernandez, Jeffrey L. Saver, Gregg C. Fonarow, Eric Edward Smith, Deepak L. Bhatt, Lee H. Schwamm, Mathew J. Reeves, Roland Matsouaka et al. · 2022 · JAMA
89. Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
    Joshua Pink, Munir Pirmohamed, S Lane, Dyfrig Arwyn Hughes · 2013 · Clinical Pharmacology & Therapeutics
90. Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients With Atrial Fibrillation
    Karsten Bruins Slot, Eivind Berge · 2013 · Stroke
91. Alcohol intake and prognosis of atrial fibrillation
    Thure Filskov Overvad, Lars Hvilsted Rasmussen, Flemming Skjøth, Kim Overvad, Ida Ehlers Albertsen, Deirdre A. Lane, Gregory Y.H. Lip, Torben Bjerregaard Larsen · 2013 · Heart
92. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial
    on behalf of the APACHE-AF investigators, Koen M. van Nieuwenhuizen, H. Bart van der Worp, Ale Algra, Laurens Jaap Kappelle, Gabriël J.E. Rinkel, Isabelle C. Van Gelder, Roger E. G. Schutgens, Catharina J.M. Klijn · 2015 · Trials
93. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study
    Martin James O'Donnell, John W. Eikelboom, Salim Yusuf, Hans‐Christoph Diener, Robert G. Hart, Eric Edward Smith, David J. Gladstone, Mukul Sharma, Rafael Dias, Greg Flaker et al. · 2016 · American Heart Journal
94. Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics
    Ravi B. Patel, Muthiah Vaduganathan, Sanjiv Jayendra Shah, Javed Butler · 2016 · Pharmacology & Therapeutics
95. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation
    Jung‐Im Shin, Alex M. Secora, G. Caleb Alexander, Lesley A. Inker, Josef Coresh, Alex R. Chang, Morgan Erika Grams · 2018 · Clinical Journal of the American Society of Nephrology
96. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study
    Duncan Wilson, Gareth Ambler, Gargi Banerjee, Clare Shakeshaft, Hannah Cohen, Tarek Ahmed Yousry, Rustam Al‐Shahi Salman, Gregory Y.H. Lip, Henry Houlden, Martin M. Brown et al. · 2018 · Journal of Neurology Neurosurgery & Psychiatry
97. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients
    Ariel Dogliotti, Ernesto Paolasso, Robert Patrick Giugliano · 2013 · Heart
98. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
    Andrew M. Demchuk, Patrick Yue, Elena Zotova, Juliet Nakamya, Lizhen Xu, Truman John Milling, Tomoyuki Ohara, Joshua Norkin Goldstein, Saskia Middeldorp, Peter B. Verhamme et al. · 2021 · Stroke
99. Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin
    Álvaro Alonso, Lindsay G.S. Bengtson, Richard F. MacLehose, Pamela L. Lutsey, Lin Y. Chen, Kamakshi Lakshminarayan · 2014 · Stroke
100. Systematic review with meta‐analysis: the risk of major gastrointestinal bleeding with non‐vitamin K antagonist oral anticoagulants
     Daniel Caldeira, Márcio Barra, A. Ferreira, A. Rocha, Abrahão Augusto, Fausto José Pinto, João N. Costa, Joaquim José Ferreira · 2015 · Alimentary Pharmacology & Therapeutics